ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
TRT and prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 191018" data-attributes="member: 13851"><p><strong>Introduction</strong>: <em><span style="color: rgb(184, 49, 47)">It has been well established that male hypogonadism has a significant impact on patient quality of life and that replacement of testosterone can markedly improve symptoms and potentially offer a protective effect.</span></em> <span style="color: rgb(44, 130, 201)"><em>The connection between testosterone replacement therapy (TRT) and prostate cancer (CaP) risk has long been a contentious subject among urologists.<u> With the relatively recent introduction of the saturation model hypothesis by Morgentaler to explain androgen binding in CaP along with a growing body of retrospective studies, there has been a mounting challenge to the entrenched paradigm that TRT in hypogonadal men stimulates CaP</u>. </em></span><span style="color: rgb(184, 49, 47)"><em>This review is a relevant update for the practicing urologist seeking to gain a better understanding regarding the risk and benefit profile to TRT in a variety of CaP settings.</em></span></p><p></p><p><strong>Objective</strong>: <em><span style="color: rgb(184, 49, 47)">To perform a literature review and provide a clinically relevant update to characterize the relationship between TRT and risk of prostate cancer (CaP) in the following clinical settings: developing de novo prostate cancer, patients with known untreated localized CaP, after definitive therapy for CaP with curative intent, and in advanced prostate cancer.</span></em> <span style="color: rgb(44, 130, 201)"><em>In providing this evidence-based update to the practicing urologist, we seek to potentially impact practice patterns through a more comprehensive understanding of the risks/benefits of TRT.</em></span></p><p></p><p><strong>Methods: </strong>A literature review using the PubMed database was performed using the following independent search terms: “prostate cancer,” “testosterone therapy,” “testosterone replacement therapy,” “hypogonadism,” “radical prostatectomy,” “radiation therapy”, “advanced prostate cancer,” “metastatic castrate-resistant prostate cancer,” “bipolar androgen therapy” and “high dose testosterone therapy”. We identified English language studies and past review articles to evaluate the role of testosterone in the development of CaP, the use of TRT after CaP to treat hypogonadism, and the use of TRT as directed therapy in the advanced prostate cancer setting.</p><p></p><p><strong>Results</strong>: The vast majority of studies reviewed were retrospective in nature with relatively short follow-up periods. TRT was found to be safe and does not appear to increase the incidence of prostate cancer de novo. In men with a history of treated or untreated CaP, TRT does not appear to increase the risk of recurrence or progression of CaP. Supraphysiologic TRT appears to show clinical benefit to mCRPC patients. Well-designed randomized studies with longer-term follow-up are lacking at present.</p><p></p><p><strong>Conclusions</strong>: <em><strong><span style="color: rgb(184, 49, 47)">The concerns regarding TRT causing/worsening CaP appears to be unsupported by the available retrospective studies and urologists may give consideration to treating symptomatic hypogonadal men with a history of CaP. </span></strong></em><span style="color: rgb(44, 130, 201)"><em><strong>There also appears to be an emerging role for supraphysiologic TRT as a therapy in the advanced prostate cancer setting. </strong></em></span><span style="color: rgb(184, 49, 47)"><em><strong>Further well-designed randomized studies are warranted.</strong></em></span></p></blockquote><p></p>
[QUOTE="madman, post: 191018, member: 13851"] [B]Introduction[/B]: [I][COLOR=rgb(184, 49, 47)]It has been well established that male hypogonadism has a significant impact on patient quality of life and that replacement of testosterone can markedly improve symptoms and potentially offer a protective effect.[/COLOR][/I] [COLOR=rgb(44, 130, 201)][I]The connection between testosterone replacement therapy (TRT) and prostate cancer (CaP) risk has long been a contentious subject among urologists.[U] With the relatively recent introduction of the saturation model hypothesis by Morgentaler to explain androgen binding in CaP along with a growing body of retrospective studies, there has been a mounting challenge to the entrenched paradigm that TRT in hypogonadal men stimulates CaP[/U]. [/I][/COLOR][COLOR=rgb(184, 49, 47)][I]This review is a relevant update for the practicing urologist seeking to gain a better understanding regarding the risk and benefit profile to TRT in a variety of CaP settings.[/I][/COLOR] [B]Objective[/B]: [I][COLOR=rgb(184, 49, 47)]To perform a literature review and provide a clinically relevant update to characterize the relationship between TRT and risk of prostate cancer (CaP) in the following clinical settings: developing de novo prostate cancer, patients with known untreated localized CaP, after definitive therapy for CaP with curative intent, and in advanced prostate cancer.[/COLOR][/I] [COLOR=rgb(44, 130, 201)][I]In providing this evidence-based update to the practicing urologist, we seek to potentially impact practice patterns through a more comprehensive understanding of the risks/benefits of TRT.[/I][/COLOR] [B]Methods: [/B]A literature review using the PubMed database was performed using the following independent search terms: “prostate cancer,” “testosterone therapy,” “testosterone replacement therapy,” “hypogonadism,” “radical prostatectomy,” “radiation therapy”, “advanced prostate cancer,” “metastatic castrate-resistant prostate cancer,” “bipolar androgen therapy” and “high dose testosterone therapy”. We identified English language studies and past review articles to evaluate the role of testosterone in the development of CaP, the use of TRT after CaP to treat hypogonadism, and the use of TRT as directed therapy in the advanced prostate cancer setting. [B]Results[/B]: The vast majority of studies reviewed were retrospective in nature with relatively short follow-up periods. TRT was found to be safe and does not appear to increase the incidence of prostate cancer de novo. In men with a history of treated or untreated CaP, TRT does not appear to increase the risk of recurrence or progression of CaP. Supraphysiologic TRT appears to show clinical benefit to mCRPC patients. Well-designed randomized studies with longer-term follow-up are lacking at present. [B]Conclusions[/B]: [I][B][COLOR=rgb(184, 49, 47)]The concerns regarding TRT causing/worsening CaP appears to be unsupported by the available retrospective studies and urologists may give consideration to treating symptomatic hypogonadal men with a history of CaP. [/COLOR][/B][/I][COLOR=rgb(44, 130, 201)][I][B]There also appears to be an emerging role for supraphysiologic TRT as a therapy in the advanced prostate cancer setting. [/B][/I][/COLOR][COLOR=rgb(184, 49, 47)][I][B]Further well-designed randomized studies are warranted.[/B][/I][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
TRT and prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top